Portal de Periódicos da CAPES

Prognostic Value of S-100-β Serum Concentration in Patients With Uveal Melanoma

2003; American Medical Association; Volume: 121; Issue: 8 Linguagem: Inglês

10.1001/archopht.121.8.1117

1538-3601

Guy S. O. A. Korse,

Cellular Mechanics and Interactions

Background In cutaneous melanoma, the S-100-β serum level is recognized as a marker of metastatic disease. Objectives To determine whether S-100-β is present in the serum of patients with uveal melanoma and to test whether the serum concentration of S-100-β is related to known clinical and histopathological prognostic factors in these patients. Methods The S-100-β concentration was measured in serum samples collected from 64 patients with uveal melanoma before enucleation and from 58 healthy control subjects. A 2-site immunoluminometric assay was used to quantify the S-100-β concentration in serum. S-100-β concentrations in the serum from patients were compared with clinicopathological tumor variables, sex, occurrence of metastasis, and survival. Results Thirty-seven (57.8%) of 64 patients with uveal melanoma showed detectable levels of serum S-100-β. There was, however, no significant difference between serum levels of patients and control subjects ( P = .71). Statistical analysis showed no significant correlation between S-100-β concentration and any of the clinicopathological tumor variables, occurrence of metastases, or survival. Only sex was correlated with S-100-β serum levels, which was not observed in the control group. Conclusions In our study on patients with uveal melanoma, the S-100-β serum concentration was not correlated with any investigated prognostic factor and was not of prognostic value itself. Female patients appeared to have higher S-100-β concentrations than male patients.